HomeNewsBusinessCOVID-19 impact: Sequoia takes Surge accelerator program online

COVID-19 impact: Sequoia takes Surge accelerator program online

Surge is a 16-week program for startups in India and Southeast Asia, where startups receive company-building and cross-border support, along with $1-2 million in capital from Sequoia.

March 19, 2020 / 18:43 IST
Story continues below Advertisement

Sequoia Capital India has decided to conduct the third cohort of its startup accelerator program Surge online due to the novel coronavirus which has killed over 9,000 people and disrupted business worldwide, said a person aware of the matter, requesting anonymity.

A Sequoia spokesperson confirmed the same- “The Surge 03 program will be moving completely online. All speaker sessions, office hours and deep dives with founders, speakers and mentors will be conducted remotely”

Story continues below Advertisement

“There will be no change in the content and speakers for Surge. The sessions are being designed to ensure we continue to foster a sense of community and encourage inter-geo collaboration amongst founders,” the spokesperson added in a statement. The third batch starts on April 13, 2020.

Surge is also the second international accelerator program to go remote after Silicon Valley’s Y-Combinator said its program and Demo Day, where companies pitch to venture capitalists, will be held online.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show